The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
The STAR*D Trial: It is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression
Open accessAbstract
The STAR*D trial is the largest and most consequential antidepressant study ever conducted, with over 120 journal articles published by study investigators, innumerable citations of STAR*D's findings by other researchers, and extensive coverage in the media, thereby giving it an oversized impact on the of depression, worldwide. Funded at a cost of 35-million US dollars, STAR*D enrolled 4041 patients who screened positive for major depression while seeking routine medical or psychiatric care. In contrast most industry-funded trials, STAR*D included depressed patients with comorbid conditions, thereby increasing the generalizability of its findings and further, provided 12 months of free continuing care monitor the durability of effects.STAR*D provided up 4 steps per patient and was designed give guidance in selecting the best next-step for the many patients who fail get sufficient relief from their initial AD. Each step consisted of a 12-week, open-label trial, with an additional 2 weeks for patients deemed close remission. ADs were administered using a system of measurement-based care that involved assessing symptoms and side effects at each visit guide aggressive medication dosing ensure that the likelihood of achieving remission was maximized and that those who did not reach remission were truly resistant the medication.1, 30STAR*D allowed patients select options for randomization in steps 2 4 to empower patients, strengthen the therapeutic alliance, optimize adherence, and improve outcome2, 483 and evaluated the relative effectiveness of 11 pharmacologically distinct drug-drug combination treatments in 5 head-to-head comparisons. CT was also available as a switch or drug augmentation option in step 2, but too few patients included it as an acceptable treatment, resulting in only 101 contributing data after randomization. Therefore, CT was excluded from the step 2 switch and augmentation analyses.3,4 4Patients who achieved remission during step were encouraged enter the 12 months of free follow-up care, as were responder patients who failed attain remission but did not want continue the next step as would involve a change in medication. Remission was defined as a score of less than 8 on the HRSD, the study's prespecified primary outcome measure, and response as a 50% or greater reduction in depressive symptoms on it. The follow-up protocol strongly recommended that participants continue the previously effective acute medication(s) at the doses used in acute treatment but treating physicians were allowed make any psychotherapy, medication, or medication dose change5, 1908 they deemed necessary sustain a positive outcome during follow-up, including scheduling additional visits if depressive symptoms returned and (or) intolerable side effects emerged.6Prior Criticisms of Apparent Bias in the Reporting of STAR*D FindingsPigott and colleagues7,8 have previously criticized the investigators for the following:1) not reporting in their summary article5 remission and response rates using the prespecified HRSD but instead using the QIDS-SR, a nonblinded, clinic-administered assessment that was excluded from use as a research measure in the Research Protocol9;2) excluding from analysis patients who started on citalopram in their baseline visit and then dropped out without taking the exit HRSD despite the investigators' statement that our primary analyses classified patients with missing exit HRSD scores as nonremitters a priori1, 43 and these early dropout patients therefore should have been counted as failures as prespecified;3) asserting in their summary article a theoretical cumulative remission rate of 67% with the unrealistic provisos that this estimate assumes no dropouts, and it assumes that those who exited the study would have had the same remission rates as those who stayed in the protocol5, and4) other indicators of bias (see eTable 1). …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the STAR-D trial raises questions about the long-term effects of antidepressants and suggests overestimation of their effects (Pigott 2015).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Pigott 2015
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Patients with treatment-resistant depression have greater severity and duration of illness, disability, physical illness, incidences of hospitalization, risk of suicide, and economic costs than patients with treatment-responsive depression.[1][2][3]”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Efficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347
Self-citation
Research works printed but not linked: 4
- Trivedi MH, 2002, STAR*D clinical procedures manual [Internet]
- National Institute of Mental Health (NIMH), 2002, Sequenced Treatment Alternatives to Relieve Depression (STAR*D) research protocol
- National Institute of Mental Health (NIMH), 2013, Available limited access datasets from NIMH clinical trials: Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
- National Institute of Mental Health (NIMH), 2006, New strategies help depressed patients become symptom-free [Internet]
Cited by
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
The Role of Exercise in Preventing and Treating Depression
Schuch, F. B., & Stubbs, B. (2019) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000620 · Cited by 264
The Effects and Mechanisms of Exercise on the Treatment of Depression
Xie, Y., Wu, Z., Sun, L., Zhou, L., Wang, G., Xiao, L., & Wang, H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.705559 · Cited by 178
Munkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024886 · Cited by 151
“Observational studies also indicate that the effectiveness of antidepressants in practice is very low: in the large, publicly funded, Sequenced Treatment Alternatives to Relieve Depression study, only 3% of the 4041 enrolled patients were considered ‘in remission’ after 1 year.(39) The recent finding based on clinical…”
BackgroundDepressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136
Metadata
- Authors
- Pigott, H. E.
- Affiliations
- Chief Clinical Officer, Positive Brain Training, LLC, Juno Beach, Florida; Psychologist, Guiding Light Wellness Center, Wellington, Florida
- Corresponding author
- Pigott, H Edmund
- ORCID
- Pigott, H Edmund
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2015-01
- Volume
- 60
- Issue
- 1
- Pages
- 9-13
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- PMC
- PMC4314062
- OpenAlex
- W795371411
- Cited by
- 93
- References
- 19
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 13 · 2022: 13 · 2021: 14 · 2020: 4 · 2019: 8 · 2018: 1 · 2017: 1 · 2015: 3
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- STAR*D trial, major depressive disorder, antidepressant treatment, treatment-resistant depression, remission, treatment response, measurement-based care, antidepressant augmentation, antidepressant switching, continuation treatment, comorbid depression, generalizability of trial results, cognitive behavioral therapy, behavioral activation, interpersonal psychotherapy, transference-focused psychotherapy, psychodynamic psychotherapy
- MeSH terms
- Antidepressive Agents, Data Interpretation, Statistical, Major Depressive Disorder, Drug Administration Schedule, Drug Resistance, Humans, Psychiatric Status Rating Scales, Remission Induction, Research Design, Bias, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The STAR*D Trial: It is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. https://app.cochat.ai/papers/10.1177/070674371506000104
- The paper
- Pigott, H. E. (2015). The STAR*D Trial: It is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371506000104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.